// App-Quantinova.ai

2049 : Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.

Researchers

Presenter

  • Renke Zhou

Principal Investigators

  • Michael E. Scheurer

  • Mark R. Gilbert

  • Melissa Bondy

  • Erik P. Sulman

  • Ying Yuan

  • Yanhong Liu

  • Elizabeth Vera

  • Merideth M Wendland

  • David Brachman

  • James Bearden

  • Susan Lynne McGovern

  • Steven S. Wilson

  • Kevin D. Judy

  • H. Ian Robins

  • Grant Kirton Hunter

  • Stephanie L Pugh

  • Terri S. Armstrong

Medical Centers

  • Baylor College of Medicine, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas Health Science Center at Houston, Houston, TX

  • Willamette Valley Cancer Institute, Eugene, OR

  • University of Arizona Cancer Center/Phoenix Accruals from Arizona Oncology Services Foundation, Phoenix, AZ

  • Southeast Cancer Control Consortium, Inc., CCOP, Winston-Salem, NC

  • UPMC Cancer Centers, New Castle, PA

  • Thomas Jefferson University, Philadelphia, PA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • Intermountain Healthcare, Murray, UT

  • NRG Oncology, Philadelphia, PA

  • The University of Texas Health Science Center at Houston, Houston, TX

Locations

  • United States

Companies

  • Southeast Cancer Con

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Glioblastoma

  • Hypertension

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved